Wall Street brokerages forecast that Axovant Gene Therapies Ltd (NASDAQ:AXGT) will post earnings of ($1.15) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Axovant Gene Therapies’ earnings. The lowest EPS estimate is ($1.39) and the highest is ($0.76). Axovant Gene Therapies reported earnings of ($2.24) per share in the same quarter last year, which indicates a positive year over year growth rate of 48.7%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, November 6th.
According to Zacks, analysts expect that Axovant Gene Therapies will report full-year earnings of ($4.25) per share for the current financial year, with EPS estimates ranging from ($5.59) to ($3.47). For the next year, analysts forecast that the firm will report earnings of ($3.32) per share, with EPS estimates ranging from ($4.35) to ($2.89). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Axovant Gene Therapies.
Axovant Gene Therapies (NASDAQ:AXGT) last announced its earnings results on Friday, August 9th. The company reported ($1.23) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.34) by $0.11.
AXGT has been the topic of several recent analyst reports. Svb Leerink initiated coverage on Axovant Gene Therapies in a research report on Friday, June 21st. They set an “outperform” rating and a $18.00 target price on the stock. Leerink Swann initiated coverage on Axovant Gene Therapies in a research report on Friday, June 21st. They set an “outperform” rating and a $5.79 target price on the stock. Zacks Investment Research lowered Axovant Gene Therapies from a “buy” rating to a “hold” rating in a research report on Wednesday, August 14th. ValuEngine raised Axovant Gene Therapies from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Robert W. Baird raised Axovant Gene Therapies from a “neutral” rating to an “outperform” rating and cut their price objective for the company from $16.00 to $13.00 in a report on Monday, August 12th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $26.79.
Hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC boosted its stake in shares of Axovant Gene Therapies by 955.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,221 shares of the company’s stock worth $27,000 after buying an additional 3,821 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Axovant Gene Therapies during the first quarter valued at approximately $272,000. Jane Street Group LLC raised its holdings in shares of Axovant Gene Therapies by 28.8% during the second quarter. Jane Street Group LLC now owns 46,455 shares of the company’s stock valued at $289,000 after acquiring an additional 10,375 shares during the last quarter. Primecap Management Co. CA acquired a new position in shares of Axovant Gene Therapies during the first quarter valued at approximately $1,400,000. Finally, BlackRock Inc. acquired a new position in shares of Axovant Gene Therapies during the second quarter valued at approximately $1,482,000. 13.48% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:AXGT opened at $7.55 on Friday. The business’s 50-day moving average is $6.74 and its 200 day moving average is $4.71. Axovant Gene Therapies has a 1 year low of $3.81 and a 1 year high of $20.80. The firm has a market capitalization of $171.54 million, a P/E ratio of -0.94 and a beta of 1.26. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.70 and a quick ratio of 1.70.
Axovant Gene Therapies Company Profile
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
Featured Article: How to execute a trade ex-dividend strategy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.